Anhco Nguyen
Chief Tech/Sci/R&D Officer chez ATARA BIOTHERAPEUTICS, INC.
Fortune : 653 330 $ au 31/03/2024
Profil
Anhco Nguyen's current job is as the Executive VP, Chief Scientific & Technical Officer at Atara Biotherapeutics, Inc. Dr. Nguyen's former jobs include being the Vice President-Research & Development at Enumeral Biomedical Holdings, Inc. from 2014 to 2016, an Associate at the Center for Cancer Research at Massachusetts Institute of Technology, and a Vice President at Fate Therapeutics, Inc. Dr. Nguyen's education includes a doctorate from the University of Washington and an undergraduate degree from Harvard College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 04/03/2024 | 941 397 ( 0,73% ) | 653 330 $ | 31/03/2024 |
Postes actifs de Anhco Nguyen
| Sociétés | Poste | Début |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 10/05/2021 |
Anciens postes connus de Anhco Nguyen
| Sociétés | Poste | Fin |
|---|---|---|
| ENUMERAL BIOMEDICAL HOLDINGS INC | Chief Tech/Sci/R&D Officer | 17/08/2016 |
| Massachusetts Institute of Technology | Corporate Officer/Principal | - |
| FATE THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formation de Anhco Nguyen
| University of Washington | Doctorate Degree |
| Harvard College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| FATE THERAPEUTICS, INC. | Health Technology |
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Enumeral Biomedical Holdings, Inc.
 Enumeral Biomedical Holdings, Inc. BiotechnologyHealth Technology Enumeral Biomedical Holdings, Inc. is a biopharmaceutical company, which engages in the business of discovering and developing novel antibody immunotherapies for the treatment of cancer and other diseases. It also focuses on the development of a pipeline of next generation monoclonal antibody drugs targeting established and novel immuno-modulatory receptors. The company was founded by Barry C. Buckland, John J. Rydzewski, and Arthur H. Tinkelenberg on December 11, 2009 and is headquartered in Arlington, MA. | Health Technology |
